Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/214570
Title: | DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol |
Author: | Torres, Sara Otero Pérez, Olalla Montero Mauriz, Rosa Rodríguez Casamartina, Eduard Fort Martínez, Sandra Fontanals Estela, Ana Clopés |
Issue Date: | 1-Mar-2024 |
Publisher: | Elsevier BV |
Abstract: | Introduction: The increased risk of severe and life -threatening toxicity in patients with dihydropyridine dehydrogenase (DPD) deficiency, under treatment with fluoropyrimidines, has been widely studied. An up-to-date overview of systematic reviews summarizing existing literature can add value by highlighting most relevant information and supports decision -making regarding treatment in DPD deficient patients. The main objective of this overview of systematic reviews is to identify published systematic reviews on the association between germline variations in the DPYD gene and fluoropyrimidine toxicity. Methods and analysis: This protocol was developed following the Preferred Reported Items for Systematic Review and Meta -analysis Protocols (PRISMA-P) checklist, and the overview of systematic reviews will be reported in accordance with the PRISMA statement. PubMed, Embase, Scopus, and the Cochrane Library will be searched from inception to 2023. Systematic reviews irrespective of study designs that analyze the association between germline variations in the DPYD and fluoropyrimidine toxicity will be considered. Methodological quality will be assessed using AMSTAR2 checklist (Measurement Tool to Assess Systematic Reviews 2). Two independent investigators will perform the study selection, quality assessment, and data collection. Discrepancies will be solved by a third investigator. Registration details: Registration number in PROSPERO: CRD42023401226. (c) 2023 Sociedad Espa & ntilde;ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.farma.2023.08.009 |
It is part of: | Farmacia Hospitalaria, 2024, vol. 48, issue. 2, p. 79-82 |
URI: | http://hdl.handle.net/2445/214570 |
Related resource: | https://doi.org/10.1016/j.farma.2023.08.009 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S1130634323006931-main.pdf | 286.69 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.